By focusing on RNA and PTCT I would suggest you are acknowledging not much learned from their own trial per se. I would agree that drafting behind others does work. But it also means their own trials aren't very informative - not awesome for justifying approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.